Purna is an associate at the firm’s New York office. Her practice focuses on patent litigation and prosecution in the pharmaceutical, biotechnology, consumer products and medical device fields. Prior to…
IRVINE, Calif., June 21, 2024 – Knobbe Martens is proud to announce that multiple practices across the firm and two dozen partners were recognized nationally and regionally for outstanding work…
April 2024 Federal Circuit Newsletter (Japanese) April 2024 Federal Circuit Newsletter (Chinese) Obviousness Analysis Does Not Consider Unclaimed Limitations In Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals Usa, Inc., Appeal No….
In the latest installment of Knobbe Martens’ monthly column focused on recent noteworthy Federal Circuit decisions, partners Sean Murray and Jeremiah Helm examine the outcome of Salix Pharmaceuticals v. Norwich Pharmaceuticals….
WASHINGTON, D.C., April 23, 2024 – Knobbe Martens congratulates partner William Zimmerman and associates Justin Culbertson and Christopher Lewis on being recognized by Washington, D.C. Super Lawyers. Mr. Zimmerman was…
On December 27, 2023, Judge Thomas S. Kleeh of the United States District Court for the Northern District of West Virginia issued an order finding that Mylan (Viatris) infringed claims 4, 7, 9, 11, and 14-17 of Regeneron’s U.S. Patent No. 11,084,865 (“the ’865 patent”) after a nine-day bench trial held in June 2023.
Zach Grinovich is an associate in the firm’s Seattle office. His practice focuses on patent prosecution and litigation. While attending law school at the Texas A&M School of Law, Zach…
The Federal Trade Commission (FTC) issued a policy statement on September 14, 2023, stating that “[b]rand drug manufacturers may be harming generic competition through the improper listing of patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations, known as the ‘Orange Book.’” The FTC’s stated goal was to notify market participants of the FTC’s intent to scrutinize improper Orange Book listings to determine whether they constitute unfair methods of competition in violation of Section 5 of the Federal Trade Commission Act. On November 7, 2023, the FTC followed through on its warning by sending notice letters to more than 10 companies challenging the Orange Book listing of more than 100 patents covering products including specific asthma and other inhaler devices, Restasis multidose bottles, and epinephrine autoinjectors.
In a recent precedential opinion, the Court of Appeals for the Federal Circuit vacated an infringement judgement against Mylan (Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 2022-1889, Fed. Cir. Nov. 6, 2023). This Abbreviated New Drug Application (ANDA) litigation involved Actelion’s patents related to epoprostenol formulations, which cover Actelion’s brand name product, Veletri®, an injectable drug for treatment of severe pulmonary arterial hypertension.
Christy is a litigation associate in the firm’s San Diego office. Her practice primarily focuses on patent litigation. She represents clients in a variety of technological areas and products, including…